A Trial of Metformin in Individuals With Fragile X Syndrome
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study is a controlled trial of metformin in individuals with fragile X syndrome between
the ages of 6 and 25 years. Participants will be randomized in a double-blind design to
either drug or placebo and will attend three visits to the study site in a 4-month period for
a series of tests. The primary objectives are to assess safety, tolerability, and efficacy of
metformin in the treatment of language deficits, behavior problems, and obesity/excessive
appetite in individuals with fragile X syndrome.